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Abstract In laparoscopy, specimens have to be removed
from the abdominal cavity. If the trocar opening or the vaginal
outlet is insufficient to pass the specimen, the specimen needs
to be reduced. The power morcellator is an instrument with a
fast rotating cylindrical knife which aims to divide the tissue
into smaller pieces or fragments. The Food and Drug Admin-
istration (FDA) issued a press release in April 2014 that
discouraged the use of these power morcellators. This article
has the objective to review the literature related to complica-
tions by power morcellation of uterine fibroids in laparoscopy
and offer recommendations to laparoscopic surgeons in gy-
naecology. This project was initiated by the executive board of
the European Society of Gynaecological Endoscopy. A
steering committee on fibroid morcellation was installed and
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experienced ESGE members requested to chair an action group
to address distinct clinical questions. Clinical questions were
formulated with regards to the sarcoma risk in presumed uterine
fibroids, diagnosis of sarcoma, complications of morcellation
and future research. A literature review on the different subjects
was conducted, systematic if appropriate and feasible. It was
concluded that the true prevalence of uterine sarcoma in pre-
sumed fibroids is not known given the wide range of preva-
lences (0.45–0.014 %) from meta-analyses mainly based on
retrospective trials. Age and certain imaging characteristics
such as ‘lacunes’ suggesting necrosis and increased central vas-
cularisation of the tumour are associated with a higher risk of
uterine sarcoma, although the risks remain low. There is not
enough evidence to estimate this risk in individual patients.
Complications of morcellation are rare. Reported are direct
morcellation injuries to vessels and bowel, the development of
so-called parasitic fibroids requiring reintervention and the
spread of sarcoma cells in the abdominal cavity, which may
possibly or even likely upstaging the disease. Momentarily in-
bag morcellation is investigated as it may possibly prevent
morcellation complications. Because of lack of evidence, this
literature review cannot give strong recommendations but offers
only options which are condensed in a flow chart. Prospective
data collection may clarify the issue on sarcoma risk in pre-
sumed fibroids and technology to extract tissue laparoscopically
from the abdominal cavity should be perfected.
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Introduction
A uterine leiomyoma or myoma is a benign smooth muscle tu-
mour of the myometrium and will be referred to in this article as
fibroid. On April 17, 2014, the Food and Drug Administration
(FDA) published a press release on the website where the use of
laparoscopic power morcellation was ‘discouraged’ due to poten-
tial upstaging of uterine sarcoma [1]. The motive to do so was the
case history of a patient with a presumed fibroidwho underwent a
laparoscopic hysterectomy and morcellation of the uterus. The
fibroid turned out to be a sarcoma and at reintervention spread
of the sarcoma in the abdominal cavity was present. The FDA
reported a risk of a uterine sarcoma in patients with presumed
fibroids of 0.28%meta-analysing the data of 18 studies. As some
way of morcellation has been used for a long time by
gynaecologic surgeons to extract tissue from the vagina or the
endoscopic openings in order to enable vaginal or laparoscopic
surgery, the professional community was shocked and represen-
tatives of many scientific societies published their opinions on the
matter [2–9]. A common statement was the lack of solid scientific
data to reach strong recommendations with regard to the
counselling of patients with fibroids on the issue to
choose laparoscopic surgery with its established benefits
or for laparotomy to escape the small risks related to
morcellation of the fibroid.
This review looks at morcellation complications in cases of
presumed fibroids. Although intra-abdominal spread of endo-
metrial cancer, adenomyosis and even trophoblastic tissue by
morcellation of the uterus has been reported, these issues will
not be addressed in this paper as those diagnoses are less
unexpected by their clinical features.
To explore the available literature, the subject will be di-
vided into clinical questions:
& What is the risk of sarcoma in patients with a presumed
fibroid
& How to diagnose a uterine sarcoma and distinguish it from
a fibroid
& What are the complications of morcellation
& How to prevent morcellation complications
& What are the knowledge gaps
& Recommendations on clinical management in patients
with fibroids
The objective of this article is to formulate and grade state-
ments and recommendations on fibroid morcellation based on
the level of available evidence. The grading of articles and
recommendations was performed according to Eccles et al.
[10] (Table 1). As statements can be based on several articles,
they are treated as recommendations.
What is the risk of sarcoma in patients with presumed
fibroid(s)
Uterine fibroids are a common disorder with an estimated inci-
dence of 20–40% inwomen during their reproductive years [11,
12]. In contrast, leiomyosarcoma of the uterus is a rare entity
with an annual incidence quoted at 0.64/100,000 women [13].
According to a recently revised WHO classification of uterine
sarcomas, the myometrial pure stromal sarcoma (leiomyoma,
Smooth muscle Tumor of Unknown Potential [STUMP] and
leiomyosarcoma) is to be distinguished from the endometrial
stromal sarcoma (endometrial stromal nodule [ESN], the low-
grade endometrial stromal sarcoma and the undifferentiated en-
dometrial sarcoma). The carcinosarcoma or Mixed Müllerian
Tumor (MMT) is classified as carcinoma. Excluding the
MMT, leiomyosarcoma (LMS) accounts for 70 % and stromal
sarcoma for 30% of all uterine sarcomas [14]. Uterine sarcomas
consist 2–7 % of all uterine malignancies. Reliable figures for
the incidence of STUMP and cellular fibroids are poorly docu-
mented. In one article from a single institution over a period of
36 years, there were 18 cases of STUMP and 72 cases of uterine
leiomyosarcoma (none of which had a prior diagnosis of
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STUMP) in the hysterectomy specimens [15]. All cases of
STUMP were registered as disease free after 5 years with only
conservative management. Sarcomas spread usually by blood or
lymphatic vessels. Five-year survival ranges from 17 to 55 %.
Survival of patients with a LMS is strongly associated with the
number of mitoses per 10 high power fields (×100 magnifica-
tion): 1–4, 98 %; 5–9, 42 %; ≥10, 15 %. A LMS embedded and
confined to the uterus that is removed ‘en bloc’ is associated
with a better survival up to 83 % [14].
Methods
Two authors (TI, KP) performed a systematic review of the liter-
ature on prevalence of uterine sarcoma in patients after uterus
surgery, mostly because of presumed fibroids. Searches were
performed of Pubmed and Embase using the MESH terms “Fi-
broids and Sarcoma and uterine neoplasms”, “Myomectomy and
Complications”. Further papers were obtained from the reference
lists of papers reviewed. Two further papers were submitted for
inclusions which were unpublished manuscripts [16, 17] (Ind
et al. 2014, personal communication). Only papers with over
500 subjects were included to address the issues of publication
bias in smaller series. Further analysis using the terms above and
cross referencing with published reviews reference lists on this
subject, but with the exclusion of review articles, letters and case
reports from the analysis, 12 papers are left where the data
seemed reliable and acceptable to help answer the question [8,
16–26]. All evidence finally reviewed has been retrieved from
observational single arm cohort studies and is therefore level III
evidence. The recommendations are therefore graded as Grade C.
Results
The overall risk of not previously presumed sarcomatous change
in the uterus from all papers was 0.14 % (1 in 700). However,
there were large differences between papers with figures varying
from 0.49 % (1 in 204) [19] to 0.056 % (1 in 1,788) [16]. On
average, papers that looked at myomectomy specimens gave a
lower risk of sarcomatous change of 0.08 % (1 in 1,306) com-
pared to those that looked at hysterectomy specimens where the
overall pooled risk was 0.15% (1 in 650). The risk appears to be
age related with one study demonstrating a lower risk in patients
under 45 years of age (Ind et al. 2014, personal communication).
Discussion
This meta-analysis, based largely on peer-reviewed articles
and two submitted articles, shows a prevalence of 0.14 %
which is lower than but within the range of similar literature
reviews [1, 6]. In the current selection of studies, the small
numbers (<500) were excluded. Recently presented data, sub-
mitted for publication, however show that including small
trials brings the average reported prevalence of sarcoma down
(Pritts E, 2014, personal communication).
Table 1 Grading statements and
recommendations [10]
Adapted from Eccles M, Mason J
(2001) How to develop cost-
conscious guidelines. Health




A Directly based on category I evidence
B Directly based on:
• Category II evidence, or
• Extrapolated recommendation from category I evidence
C Directly based on:
• Category III evidence, or
• Extrapolated recommendation from category I or II evidence
D Directly based on:
• Category IV evidence, or
• Extrapolated recommendation from category I, II or III evidence
Good practice point The view of the Guideline Development Group
NICE 2002 Recommendation taken from the NICE technology appraisal
Evidence category Source
Ia Systematic review and meta-analysis of randomised controlled trials
Ib At least one randomised controlled trial
IIa At least one well-designed controlled study without randomisation
IIb At least one other type of well-designed quasi-experimental study
III Well-designed non-experimental descriptive studies, such as comparative studies,
correlation studies or case studies
IV Expert committee reports or opinions and/or clinical experience of respected authorities
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Pritts et al. selected 131 articles with 29.877 patients operated
for fibroids and found a sarcoma prevalence of 1:7,400 (0.014%).
They explain the large prevalence difference with the available
literature by includingmore prospective trials (50% half of which
randomised trials) that lack the confounder of patient selection of
retrospective trials. Also trials with smaller numbers were includ-
ed increasing the power of the meta-analysis using Bayesian sta-
tistics to correct for small patient numbers. Although the large
differences in prevalence undermine the credibility of all collected
data on the prevalence of sarcoma in presumed fibroids, it is likely
that the prevalence is much lower than recently reported. Prospec-
tive collection of multicentric data of contemporary patients may
clarify the important issue of prevalence.
As the LMS has a similar clinical and diagnostic appearance
to the leiomyoma in contrast to the endometrial stromal sarcoma,
our interest is primarily to distinguish fibroids from LMS. The
endometrial stromal sarcomas usually cause abnormal—non cy-
clic—uterine bleeding. But also LMS can present as a type 0—
100 % protruding in the uterine cavity—causing abnormal uter-
ine bleeding. In the current review, all kinds of sarcomatous
changes were included in themeta-analysis, including STUMP’s.
Thismay have blurred the prevalence results. In particular includ-
ing studies with laparoscopic supracervical hysterectomies,
sometimes without the presumption of fibroids, will result in a
lower reported prevalence. A difference in prevalence between
studies where fibroids intended to be morcellated and the older
(pathology) studies where all uteri and fibroids served as a de-
nominator in the prevalence rate has also been demonstrated [27].
Data on age and prevalence does not allow the estimation of
an accurate risk of sarcoma in the individual patient scheduled
for fibroid surgery but they may be taken into account to define
a low and intermediate risk group of patients. The paradox
remains that as presumed fibroids are less prevalent in postmen-
opause, the highest (absolute) number of sarcomas is found in
the fourth decade, although the incidence is still extremely low
[23]. In one study, 18/21 sarcoma patients (86%) were premen-
opausal [28]. The statements of this section are in Table 2.
How to distinguish a fibroid from a sarcoma by diagnostic
tests
Even if an accurate distinction between fibroids and sarcomas by
preoperative diagnostic test is not possible, potential specific char-
acteristics of both disorders would enable the clinician to better
predict the presence of sarcoma in a presumed fibroid and counsel
patients likewise. Uterine sarcomas are characterised by the com-
mon oncologic features such as growth, necrosis and increased
vascularity. However, these characteristics occur also in fibroids.
Although the focus of this overview is on fibroid
morcellation, the same may be applicable to other therapeutic
options such as selective uterine artery embolisation, fibroid
ablation, hysteroscopic resection or medical treatment.
In this section, the evidence is reviewed as to the predictive
value of imaging and other diagnostic tests in differentiating
between a (benign) fibroid and a LMS of the uterus.
Methods
One of the authors (TvdB) performed a systematic Medline
search of the literature in order to map the different diagnostic
tests and their characteristics. The following search terms were
used: “uterine leiomyosarcoma” [all fields], “diagnosis” [all
fields], “ultrasonography” [all fields], “LDH” [all fields] or
“LDH isoenzymes” [all fields] and “markers” [all fields]. Af-
ter including cross references, 37 articles were available for
further consideration [22, 28–64].
Imaging (US, MRI)
There are no pathognomonic features predicting a LMS on
any imaging technique [29, 30, 36]. Rapid increase in size
(within 3 months) has been reported in case reports of LMS
[48, 59] but is generally not distinctive as it may occur in
fibroids as well [22]. No growth—in 3 months—may be
reassuring unless caused by GnRH [65, 66]. Not only can
the uterine sarcoma be accompanied by fibroids responding
to GnRH, but it may also be sensitive for estrogen deprivation
itself due to its estrogen receptors. It has been reported in a
group of 21 uterine sarcomas that all but one (95%) was either
solitary or in case of several myometrial lesions the largest
[64]. Another study with ultrasound compared eight LMS
and three STUMPs with 225 fibroids and reported that LMSs
were significantly larger than other uterine smooth muscle
tumours [35]. Theywere all solitary, and seven of eight lesions
had a diameter ≥8 cm. Degenerative cystic changes were ob-
served in four lesions, and increased peripheral and central
vascularity was demonstrated in seven lesions. Sensitivity,
Table 2 Statements on the prevalence of uterine sarcoma in presumed
fibroids
Statements Evidence
The incidence of leiomyosarcoma is 0.64/100,000 per year
The prevalence of sarcoma in a presumed fibroid is 0.14 %
(1:700) with a range from 0.49 % (1:204) to 0.014 %
(1:7,400). This large range renders more prospective data
collection necessary.
C
The risk of sarcoma in presumed fibroids is positively related
to age, although the majority of sarcomas—in absolute
numbers—will be in the fourth decade. Below the age of 40
sarcoma in a presumed fibroid is extremely rare.
C
Based on age, an accurate assessment of the risk of sarcoma in
patients with presumed fibroids is not possible although a
global estimation (intermediate risk versus low risk) could
be made
C
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specificity and positive predictive value of increased central
and peripheral vascularity in the diagnosis of LMS were 100,
86 and 19%, respectively. Combining other sonographic find-
ings with marked central vascularity, the positive predictive
value increased to 60%, but sensitivity decreased to 75%. 2D
ultrasound Power Doppler (USPD) may be related to the na-
ture of the tumour, with a peak systolic velocity having a
sensitivity of 80 % for detecting sarcoma with a specificity
of 97 %. No studies on sarcoma diagnosis have been pub-
lished on vascular indices measured by 3D USPD.
Although LMS may have on ultrasound and MRI a similar
appearance to fibroids [30, 36], a large >8 cm, solitary, oval-
shaped, highly vascularised (peripheral and central) and irreg-
ular, heterogeneous myometrial tumour with central necrosis/
degenerative cystic changes and absence of calcifications
should raise the suspicion of a LMS [29, 30, 35, 41]. MR
imaging is superior to CT scan to delineate the extent and to
evaluate the tissue characteristics of the lesion [43]. MRI,
especially the T2-weighted sequences, may help evaluating
tumour extension in the uterus [47] and in differentiating be-
tween a leiomyoma and a LMS [51, 54]. In a small series,
contrast enhancement after administration of gadolinium
(Gd)-DTPA was detected in all 10 LMS, but absent in 28 of
32 uterine degenerated leiomyoma patients [39].
PET scan
Positron emission tomography has a place in the diagnostic
armentarium of presumed fibroids. In PET scanning, a radio-
nuclide (tracer) on a biologically active molecule is visualised.
In imaging of fibroids, usually fluodeoxyglucose (FDG) is
used, but also other molecules, such as deoxyfluorothymidine
(FLT) or alphafluorobeta-estradiol (FES), have been reported.
In general, the uptake of FDG in a fibroid is associated with
the estrogen status, cellularity and the presence of malignancy
[62]. One retrospective study compares different imaging
techniques in the case of suspected uterine sarcoma. Of the
five sarcomata, all were detected by FDG PET, four by dy-
namic MRI and two by PowerDoppler ultrasound [58]. FES
may be more accurate in distinguishing LMS from fibroids
than FDG, with an accuracy of respectively 93 and 81 % [67].
Serum markers (LDH and CA125)
In a prospective series of 227 patients, the total LDH and LDH
isozyme type 3 were elevated in all 10 patients with LMS as
compared with degenerated leiomyomas [39]. Elevated
CA125 have been reported in patients with LMS, especially
in advanced-staged LMS [44, 59]. In a series of 42 consecu-
tive LMS, the values of preoperative serum CA125 were sig-
nificantly higher in the uterine LMS group than those in the
uterine leiomyoma group. However, there was significant
overlapping of preoperative serum CA125 between the
uterine leiomyoma group and early-stage uterine LMS which
limits the clinical use [44].
Histology
The role of endometrial sampling without abnormal uterine
bleeding in the detection of uterine sarcoma is not yet eluci-
dated [68]. In a large series of 938 malignant tumours in hys-
terectomy specimens from a pathology laboratory, 142 speci-
mens with sarcomas were found of which 72 (51 %) had
endometrial sampling. In 62/72 (86 %), the sampling was
positive for sarcoma. As preoperative abnormal uterine bleed-
ing was not registered and analysed in this study, it is not clear
which patients were selected for endometrial sampling. It may
be assumed that abnormal uterine bleeding was the indication
for endometrial sampling in sarcoma patients and not the pre-
sumed fibroid itself.
Also the role of image-guided needle biopsies is not
completely clear. The predictive value of a negative biopsy
might be expected to be low because of the large areas of
necrosis, an excellent negative predictive value is reported
using MRI-guided needle biopsies and Bell’s classification
on histology [31] with a cut-off level of 2 [45]. With this
cut-off level, chosen not to miss malignancy, the sensitivity,
specificity, positive and negative predictive values were 100,
98.6, 58 and 100.0 %, respectively. No data are found on the
possible spread of sarcoma cells by multiple puncturing of the
sarcoma. In breast cancer needle puncture, an increase of pos-
itive lymph nodes compared to breast tumours that were not
punctured was found [69]. On the other hand, incisional biop-
sy of melanoma has no apparent effect on tumour spread [70].
Tulandi et al. [55] report on two cases of multiple
transabdominal biopsies and frozen section before proceeding
with morcellation.
Finally, it should be stressed that even the histological di-
agnosis of LMS on an intact hysterectomy specimen may be
difficult because of locally differing diagnostic criteria [31,
38]. Statements on diagnosis of uterine sarcoma are listed in
Table 3.
What are complications of morcellation?
A complication can be defined as an unintended and undesir-
able event following clinical management resulting in its ad-
justment or irreversible injury to the patient. Known compli-
cations are direct morcellation injuries where the activated
morcellator injures intestines or blood vessels. Secondary to
morcellation of fibroids, chips can implant on the peritoneum
causing parasitic fibroids which may need further surgery. If a
presumed fibroid appears to be a sarcoma (or other malignan-
cy), any method of morcellation disrupts the integrity of the
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tumour, possibly upstaging the disease and affecting survival.
In case of power morcellation, the centripetal forces of the
cylindrical knife may add to the phenomenon of ‘seeding’ of
tumour cells on the peritoneum. Finally, the fragmental state of
the specimen due to morcellation may impair proper selection
for histologic evaluation of that part of the tumour that is sus-
picious of malignancy. This might cause treatment delay. In
this section, these complications will be discussed separately.
Direct morcellation injuries
In the field of gynaecology, the majority of symptomatic
masses are represented by uterine fibroids. During operative
laparoscopy, power morcellation is indispensable to remove
large tissue fragments while the laparoscopy offers quicker
recovery, less post-operative pain, fewer wound compli-
cations and less post-operative morbidity than open pro-
cedures. In addition, power morcellators shorten the
time of surgery significantly. An ‘electrical cutting de-
vice for laparoscopic removal of tissue from the abdom-
inal cavity’ was introduced by Steiner in 1993 [71].
Similar instruments according to the Steiner principle
have been commercialised since.
Despite the well-established advantages of power
morcellation during laparoscopy, the use of powermorcellators
is not completely without concern. Milad [72] reviewed the
FDA’s adverse event database “MAUDE” between 1992 and
2013, where injuries to the small/large bowel (31), large blood
vessels (27), the kidney (3), ureter (3), bladder (1) and dia-
phragm (1) have been reported using power morcellation. In
six cases, the accidents were fatal. This underlines that direct
morcellation injuries are serious and, though underreported,
extremely rare. It is recommended to maintain adequate dis-
tension and use morcellators with a nozzle to promote lateral
pealing preventing the morcellator from coring the tissue and
thereby losing the morcellator’s tip out of sight [73].
Parasitic fibroids
Traditionally, parasitic fibroids were thought to be peduncu-
lated subserosal fibroids that were accidentally separated from
the uterus and had become attached to another organ in the
pelvis for their blood supply (3). The increasing number of
case reports of parasitic fibroids after the use of laparoscopic
morcellation has contributed to the development of an iatro-
genic theory. It is thought that seeding of retained small tissue
fragments after morcellation can lead to the development of
parasitic fibroids in the peritoneal cavity [74]. Most patients
presented with symptoms such as abdominal or pelvic pain,
dyspareunia, abdominal distension, urinary frequency and
constipation. One of five patients is asymptomatic and the
presence of a pelvic mass unexpectedly diagnosed during rou-
tine examination or another surgical procedure. Additional
published cases indicated that although rare, parasitic fibroids
can occur long after laparoscopic morcellation and are often
asymptomatic or present with abdominal or pelvic pain. Little
is known about the incidence and risk factors of this
phenomenon.
To answer questions about the incidence, risk factors and
other characteristics of parasitic fibroids, one of the authors
(HP) conducted a systematic literature search the MEDLINE
and Embase databases. The report of this systematic review
will be submitted elsewhere.
The overall incidence of parasitic fibroids after laparoscop-
ic surgery with the use of morcellation was reported to be
between 0.12 and 0.9 % [75–77]. The reported incidence of
parasitic myomas after laparoscopic myomectomy was 0.2–
1.2 % [76, 78, 79].
With regards to the risk factors, gonadal steroids hormones
are known to influence the growth of uterine fibroids. It is
hypothesised that prolonged exposure to steroid hor-
mones (e.g. hormonal replacement therapy) during post-
menopause could be a risk factor for the development
of parasitic fibroids. In case of parasitic fibroids, there
is often more than one. Statements on parasitic fibroids
are listed in Table 4.
‘Upstaging’ uterine sarcoma
Although reducing a uterine sarcoma with electromechanical
power morcellation within the abdominal cavity is contrary to
Table 3 Statements on diagnostic tests for uterine sarcoma
Statements Grade
There are no features predicting a leiomyosarcoma (LMS) on
any imaging technique with certainty
C
A large (≥8 cm), solitary, oval-shaped, highly vascularised
(peripheral and central) and irregular, heterogeneous
myometrial tumour with central necrosis/degenerative cystic
changes and absence of calcifications must raise the suspicion
of a LMS
D
Rapid increase in size (within 3 months) has been reported in
LMS but is generally not distinctive as it may occur in fibroids
as well. No growth—in 3 months—may be reassuring unless
in combination with GnRH
C
MRI with contrast enhancement may prove helpful in
differentiating between LMS and fibroid
C
Total LDH and LDH isozyme 3 may help in differentiating
between LMS and fibroid
C
CA125 may be elevated in advanced staged LMS but seems not
useful in early stage LMS
C
Endometrial sampling in the detection of uterine sarcoma is
indicated in abnormal uterine bleeding. Without abnormal
uterine bleeding its role is unclear
D
Transcervical or transabdominal needle biopsy may prove of help
in differentiating between LMS and a fibroid, although no data
are available on spread of tumour cells caused by the biopsy
needle
D
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oncologic surgical principles, the question remains if sarcoma
cells are more inclined to implant in the peritoneum after
power morcellation then after ‘en bloc’ removal of the uterine
specimen with sarcoma embedded and if survival is affected
given the bad prognosis that the sarcoma already has. These
two questions have been addressed in literature. Two case
reports support the concept of upstaging by power
morcellation [80, 81]. In the reported patients, reintervention
showed seeding of sarcomatous tissue, which was not visible
during initial surgery. These findings have been confirmed in
larger studies where the percentage upstaging ranged from 15
to 64 % [18, 28, 82, 83].
Not only electromechanical power morcellation is associ-
ated with the risk of upstaging but also other ‘manipulations’
of the sarcomatous tumour, such as myomectomy by laparot-
omy, subtotal hysterectomy and hysteroscopic resection of
submucous fibroids, may affect survival suggesting upstaging
[84]. The question as to whether seeding affects survival is
also addressed by Seidman et al. [18]. In four of seven patients
with LMSwhowere extracted by power morcellation, seeding
was visible during reintervention. Three patients died from the
disease and one was alive with metastatic disease. Three pa-
tients with morcellated sarcoma without signs of seeding were
alive without metastases.
Two studies by Park et al. [85, 86] compared the survival of
patients with uterine sarcoma with (n=48) and without
morcellation (n=58) during surgery and demonstrated a sig-
nificant difference of survival in favour of the non-morcellated
group (Table 5). Although confounding factors cannot be ex-
cluded in these retrospective trials, an effect in favour of the
morcellation group would have been expected as clinical sus-
picion of sarcoma based on size and imaging texture could
have resulted in a worse prognosis in the laparotomy group.
Recently, a literature review was published by Pritts et al.
[87] where she critically appraised the studies that reported on
upstaging of sarcoma by morcellation which she evaluated as
‘rather poor’. Although this weakens the alarming statements
on upstaging, it does not prove the contrary (the innocence of
open morcellation of sarcoma) and underlines the need for
further studies. Statements on upstaging of uterine sarcoma
by morcellation are listed in Table 6.
Missing the diagnosis of malignancy because of shredded
material
Morcellated specimens are poorly amenable to pathologic ex-
amination because the morcellation abolishes many of the
anatomic features that allow meaningful gross description,
including the notions of orientation, dimension, adjacency,
border and margin [88]. This has been described in other uter-
ine malignancies and could lead to delayed diagnosis or sub-
optimal staging, causing treatment delay [89, 90].
How to prevent morcellation complications
Given the scarcity of direct morcellation injuries, no clinical
trials are available and all suggestions to prevent them may be
considered as good practice points. With regards to preventing
direct morcellation injuries, the options are listed in Table 7;
regarding the development of parasitic fibroids, the options
are mentioned in Table 8. The options to prevent upstaging
of uterine sarcomas by power morcellation will be presented
under the final options in Table 10.
Table 5 Studies that compared patients operated for uterine sarcoma
with and without morcellation. With permission from Nederlands
Tijdschrift voor Obstetrie en Gynaecologie [27]
Park 2011
(LGESS)
No. Age FU Recurrence 5 years
DFS
ORmv
Morcellation − 27 45.3 64 3/27 84 %
Morcellation + 23 43.6 66 8/23 55 % 4.03 (1–15)
Park 2011 (LMS) n Age FU Recurrence 5 years
DFS
OR
Morcellation − 31 47.9 52 7/31 65 %
Morcellation + 25 46.4 27 13/25 40 % 3.11 (1–9)
LGESS low grade endometrial stromal sarcoma, LMS leiomyosarcoma,
FU follow-up, DFS disease free survival, ORmv odds rate mortality risk
after morcellation in a multivariate analysis
Table 6 Statements on the complication of morcellation ‘seeding’
(upstaging uterine sarcoma)
Statements Grade
The quality of research regarding upstaging of uterine sarcoma by
open morcellation is rather poor
D
Electromechanical power morcellation of an unsuspected uterine
sarcoma may cause intraperitoneal dissemination (‘seeding’)
C
Intraperitoneal dissemination (‘seeding’) may be associated with
lower survival rates
C
‘En bloc’ resection of a uterine sarcoma may be associated with
better survival than other tissue retrieval methods going with
tumour injury
D
Table 4 Statements on parasitic fibroids by previous morcellation
Statements Grade
The overall incidence of parasitic fibroids after laparoscopic
surgery with the use of morcellation is reported to be
between 0.12 and 0.9 %
D
The reported incidence of parasitic fibroids after laparoscopic
myomectomy is 0.2–1.2 %
D
Premenopausal status and hormonal replacement treatment
after primary surgery may be considered as risk factors for
the development of parasitic fibroids, however not specific
D
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Knowledge gaps
The—on some issues—systematic literature search on which
this review is based revealed some serious gaps in available
knowledge. Due to the low prevalence of uterine sarcomas,
most data on prevalence and risk factors are derived from case
histories or retrospective trials with low numbers. Prospective
data collection of patients after fibroid surgery on age, imag-
ing and laboratory results and subsequent histology is needed
to answer questions on individual risk estimation in order to
enable the patient to give a well-considered consent prior to
minimal invasive surgery.
The development of safer morcellation techniques in the
abdominal cavity by technical innovation, including in-bag
morcellation, is in its infancy. No doubt that safe in-bag
morcellation of fibroids has the potential to avoid many of
the reported morcellation complications, such as direct
morcellation injuries, parasitic fibroids and the upstaging of
morcellated sarcomas. However, not all risks are addressed
such as spillage from the content of the bag in the abdomen
especially if the bag is punctured to introduce a laparoscope in
the bag for better visualisation of the morcellator’s tip. The
in vitro results are promising. Cohen and Einarsson [91] dem-
onstrated in-bag morcellation in an in vitro study, in which
they successfully morcellated beef tongue specimens. In only
1 of the 13 trials did leakage of the bag occur. Washings of the
container after retrieval of the specimen bag were negative for
muscle cells, except for the open control and the trial with
leakage of the retrieval bag. A small series of in-bag
morcellation have been published with good results [92, 93].
Vaginal morcellation in a bag has been described also [94].
Possible draw backs are the need for a sufficient vaginal entry
and the fact that only hysterectomy specimens are suitable for
this technique. Future studies must establish the role of vagi-
nal in-bag morcellation.
In urology in-bag (‘contained’) morcellation has been per-
formed in low-grade renal cell carcinoma (RCC). In a retro-
spective study, Wu et al. [95] evaluated in-bag morcellation in
188 patients with low-stage RCC. After a mean follow-up of
21 months, no difference in survival was demonstrated com-
pared to open nephrectomy, although one port site metastases
occurred. The safety and effectiveness in terms of survival
was confirmed in another study [96]. In low-grade renal cell
carcinoma, laparoscopic approach combined with in-bag
morcellation of the kidney appears to be safe and effective.
Port site metastases after morcellation are thought to be
related to the laparoscopic approach itself and not to the
morcellation technique as exteriorising the bag before
morcellation is meant to prevent contact of the tumour with
Table 7 Options to prevent direct morcellation injuries
Options Grade
For safe entry, enlarge the skin and fascia incision to the




Make sure that the morcellator’s blade remain locked
inside the protecting tube during the morcellator
insertion into the abdomen
Good practice
point
Keep the tip of the morcellator shaft in midline of the
lower abdomen while introducing the device into the
abdominal cavity and during morcellation
Good practice
point
Morcellate only under continuous vision by applying
the lateral pealing technique. Prevent penetrating the
mass and losing the tip out of sight
Good practice
point
Morcellation close to the intestine or to blood vessels
increase risk of injury to these structures
Good practice
point
Table 8 Statements and options on preventing parasitic fibroids after
morcellation
Statements and options Grade
The small risk of parasitic fibroid with laparoscopic
morcellation (<1 %) should be discussed with the




Avoid spread of cells and tissue fragments in the




When morcellation is used, efforts should be made to
prevent tissue loss during morcellation and to remove
all tissue fragments after morcellation:
Place the patient in reverse Trendelenburg position after
morcellation and irrigate the abdomen and pelvis
extensively
After irrigation of the peritoneal cavity the abdomen




The potential increased risk of parasitic fibroids after
sex steroid exposure (endogenous/exogenous) after
laparoscopic morcellation should be considered
before hormonal replacement therapy is prescribed
D
Table 9 Statements on technical innovation
Statements Grade
Research on technical innovation in tissue retrieval from
the abdominal cavity mainly focusses on in-bag
(‘contained’) morcellation
D
In-bag morcellation may prevent morcellation
complications such as direct morcellation injuries,




Potential reported risks of in-bag morcellation is spillage
of tumour cells from the bag
C
In urology in-bag morcellation after laparoscopic
removal of early stage and low grade renal cell
carcinoma is reported to be safe and effective
C
Vaginal in-bag morcellation has also been described and
needs further study
D
Development of bags is needed as well as registration
of cases to further establish the potential value of
on in-bag morcellation in gynaecologic surgery
Good practice
point
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the abdominal wall. In a review on port site metastases, the in-
bag morcellation technique is recommended to prevent port
site metastases [97].
Two studies report on the techniques of containment.
Parekh et al. [98] suggested that specimens should be
morcellated in fluid-filled retrieval bags. In an in vitro study,
five porcine kidneys were morcellated. No perforation or leak-
age occurred in the fluid-filled bags compared to one perfora-
tion in ‘dry’morcellation. Also, morcellation timewas shorter,
when compared to the dry bags.
Meng et al. [99] suggested that washings of a specimen
retrieval bag may help the pathological diagnosis after renal
morcellation. In their prospective study, 22 consecutive wash-
ings were examined. In 9 of 13 patients with carcinoma, the
cytological examination confirmed pathology and in three
cases cytology provided additional information. In all nine
benign cases, cytology was consistent with pathology.
The potential benefits and risks of in-bag morcellation
should be further evaluated by clinical studies before it can
be recommended in general practice. Furthermore, although
in-bag morcellation appears to be very promising as a tool for
the prevention of morcellation-related complications, further
research is needed to improve the morcellation mechanism
itself [100]. The statements on knowledge gaps and potential
technical innovations are listed in Table 9.
Concluding remarks
In the previous sections, the results of a literature search are
shown to answer questions about fibroid morcellation in lap-
aroscopy, related complications and what is needed to prevent
them. It has not been the aim of this study to address
morcellation of other structures such as uteri without pre-
sumed fibroids (e.g. some cases of LSH) or morcellation of
ovarian masses.
As expected, the level of evidence is not sufficient to give
recommendations. Therefore, it was decided to present op-
tions (Table 10), which are condensed in a flowchart to offer
structure in the clinical management (Fig. 1). The flowchart
can at best support the clinician to pursue safe and effective
fibroid treatment but ‘reassuring’ does not exclude sarcoma
Table 10 Options in intended fibroid morcellation
Options and considerations
Informed consent by the patient is the corner stone
of preoperative workup. If fibroid morcellation is
intended, include its possible complications in the
informed consent procedure before operation.
Good practice
point
Standardise the clinical management by using a
flowchart to classify patients according to global risk
of a sarcoma in a presumed fibroid. Use flowchart in
the figure as an option.
Good practice
point
Use transvaginal ultrasound, transabdominal ultrasound
or in case of poor visualisation on ultrasound MRI
with or without contrast (Gadolinium-DTPA)
D
Consider including vascularity parameters (RI and PSV
in 2D PowerDoppler ultrasound (PDUS) or vascular
indices in 3D PDUS)
D
Consider performing LDH and iso-enzyme 3 assay D
Perform a preoperative endometrial aspiration in case of
abnormal uterine bleeding
D
Support the development of potentially beneficial
techniques to prevent morcellation complications
by participating in clinical trials
Good practice
point
Register patient’s data after her consent including
pre-surgery images and post-surgery histology
Good practice
point
Fig. 1 Flowchart of intended
fibroid morcellation
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and in ‘non-reassuring’ cases the diagnosis will likely be be-
nign. Therefore, it cannot have the status of guideline.
The ‘additional characteristics’ in the flowchart for women
over 40 years of age are based on the literature review in the
previous sections. These characteristics have been associatedwith
discrimination of sarcomas from fibroids but they lack thorough
scientific evaluation. In the case of LDH, the predictive value is
based on only one trial [39].We have to realise we are looking for
a needle in a haystack indeed. This means that for each single
‘risk factor’, we can easily argue that it is of no importance.
However, the association of several risk factors is probably more
relevant than a single one. If more risk factors are present, it might
be wise to be prudent, although the risk of sarcoma remains low.
Fibroid growth has been discussed among the authors at
length and it was concluded that ‘growth’ or ‘rapid growth’
are not specifically associated with sarcoma but also with
fibroids. On the other hand, a stable size during several
months without administration of suppressing hormones
(GnRH or Ullipristal) does make a sarcoma highly unlikely.
Growth of the presumed fibroids during GnRH treatment or in
menopause should raise suspicion about the nature of tumour.
The in-bag morcellation of presumed fibroids has the po-
tential to prevent the rare morcellation-related complications
typical of ‘open’ morcellation, such as direct morcellation
injuries by distending the morcellation bag, the spread of fi-
broid chips, sarcoma or other malignant particles and cells in
the abdominal cavity. More research is needed to improve the
technique and on safety before in-bag morcellation can be
recommended as a general tool in laparoscopic surgery.
We have chosen not to list all the literature on the benefits
of laparoscopic surgery which are an important argument in
the trade-off between laparoscopy with morcellation and lap-
arotomy without. The vast amount of evidence in favour of
laparoscopy is elegantly abstracted in the ‘second look’ article
by Pitkin and Parker [101].
Taking needle biopsies before surgery would be an inter-
esting option in case of intended fibroid surgery to rule out
sarcoma; however, there are different opinions on the potential
harmful effects of tumour manipulation and spread by needle
biopsy [45, 69, 70]. Also representativeness of needle biopsies
may be a yet unresolved drawback, given the necrotic areas in
the sarcoma.
It is clear that there is much research to be done. At first, the
issue on sarcoma risk in patients scheduled for fibroid
morcellation should be clarified. The preliminary report of
Pritts et al. (2014, personal communication) that includes
more prospective trials and is based on sound statistics shows
much lower prevalences (1:7,400) than previously reported in
the meta-analyses based on retrospective trials (1:352) [1].
Secondly, more data must be collected to estimate the risk
of sarcoma in individual patients with presumed fibroids,
based on epidemiological data from the patient and diagnostic
tests such as imaging.
Thirdly, technical innovation, such as in-bag morcellation,
should enable safe morcellation of intra-abdominal specimens.
A corner stone in the doctor and patient relationship is the
informed consent procedure. This means that the patient needs
to be informed as completely as possible and based on the best
available evidence in order to let her make the best choice of
treatment tailored to her individual situation.
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